Jemperli (Dostarlimab-gxly)

Jemperli is a PD-1–blocking antibody used for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following previous treatment with a platinum-containing regimen and solid tumours, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. 

Recommended Dosage: The proposed dosage of Jemperli is: 

• Dose 1’st through Dose 4’th: 500 mg every 3 weeks. 
• Subsequent dosing beginning 3’rd weeks after Dose 4’th (Dose 5’th onwards): 1,000 mg every 6 weeks. 

Healthcare professionals recommend the dosage of Jemperli to be administered as an intravenous (IV) infusion over 30 minutes. Treat patients until the disease is progressive or unacceptable toxicity occurs

• Certain immune-mediated adverse reactions, which may be severe or fatal, can emerge in any organ system or tissue. Immune-mediated adverse reactions can emerge anytime after starting a PD-1/PD-L1–blocking antibody.
• One should monitor precisely for signs/symptoms that may be clinical manifestations of underlying immune-mediated adverse reactions. Assess liver enzymes, creatinine, and thyroid function tests at baseline and periodically during Jemperli 500 mg treatment. 
• Certain life-threatening infusion-related reactions have been noted with PD-1/PD-L1–blocking antibodies. Evaluate patients for signs/symptoms of infusion-related reactions. Interrupt or slow the infusion rate or permanently discontinue this therapy depending on the severity of the reaction. 
• Depending on its mechanism of action, the Jemperli injection can be responsible for causing fetal harm when administered to a pregnant woman. Do not breastfeed during treatment with this medicine and for 4 months after the last dose. 
• Fatal and other severe complications can emerge in patients who receive allogeneic HSCT before or after being treated with a PD-1/PD-L1–blocking antibody. Follow patients precisely for findings of transplant-related complications and intervene promptly.

What documents are required to import JEMPERLI to India?

JEMPERLI (dostarlimab-gxly) injection can be imported by patients or government hospitals only in the name of the patients. 

The following documentation is needed to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patients Identity proof (issued by Govt of India)

 How does the order confirm?

 The order will be confirmed only after the receipt of:

• A valid prescription by healthcare professionals.
• Import permit if applicable.

 Is JEMPERLI available in India?

 JEMPERLI (dostarlimab-gxly injection) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Jemperli injection in India.
• Medicine Price.
• Finding Genuine and reliable sources from Canada, Europe, the USA and Australia
• Ensuring 100% transparency.

JEMPERLI can be made available to patients, doctors and hospitals in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after receiving a valid prescription from the doctor and import permit.

IPN (Indian Pharma Network) can facilitate the supply of JEMPERLI (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable)

Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for jemperli price in India. 

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.